Shanghai Fosun Pharma: Citi Maintains Buy Rating (HK$35.30 Target)
Citi reaffirmed its ‘Buy’ rating on Shanghai Fosun Pharmaceutical (Group) Co. (SFOSF) late Tuesday, projecting a price target of HK$35.30 despite current trading around HK$18.79. This bullish outlook, coupled with ... Read More